ArticleAnnals of surgical oncology2026
Clinical Outcomes of First-Line Immune Checkpoint Inhibitor-Based Therapy for Postoperative Recurrence After Adjuvant Nivolumab in Esophageal Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant nivolumab has become a standard treatment after curative resection for locally advanced esophageal cancer; however, postoperative recurrence remains common. The efficacy of immune checkpoint inhibitor (ICI)-based therapy for postoperative recurrence in patients treated with adjuvant nivolumab remains unclear. This study evaluated the clinical outcomes of first-line ICI-based therapy for postoperative recurrence, focusing on the impact of prior adjuvant nivolumab exposure.
methodsThis single-center retrospective study included 81 patients who developed postoperative recurrence after radical esophagectomy and subsequently received first-line ICI-based therapy. Propensity score matching (PSM) was performed to adjust for baseline differences. Treatment outcomes were assessed based on treatment response, progression-free survival, and overall survival (OS) after recurrence.
resultsAmong the 81 patients, 27 had received adjuvant nivolumab and 54 had not. Treatment responses, including the proportion of patients achieving early tumor shrinkage ≥ 20%, were similar between patients with and without prior adjuvant nivolumab exposure. After PSM, no statistically significant differences were observed in treatment response. No significant differences were observed in progression-free survival (hazard ratio 1.4, 95% confidence interval 0.74-2.64, p = 0.298) or OS (hazard ratio 1.23, 95% confidence interval 0.61-2.50, p = 0.56). Two-year OS was 44% and 42.9% in the adjuvant and non-nivolumab groups, respectively.
conclusionsFirst-line ICI-based therapy for postoperative recurrence demonstrated no statistically significant differences in clinical outcomes irrespective of prior exposure to adjuvant nivolumab, suggesting that previous adjuvant immunotherapy does not preclude clinical benefit from subsequent ICI-based therapy at recurrence.
Indexed as
Identifiers
42159877What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.